Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells
is a potent PDK1 inhibitor
Cells are trypsinized
which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD)
SPR741 TFA Size:Contact [email protected] for quotation acting as a transition-state analogueSPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 TFA increases the permeability of the outer membrane of Gram negative bacteria and is used to treat severe Gram negative bacteria infections. SPR741 TFA inhibits multidrug resistant Gram negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 TFA. Product information Molecular Weight: